ROY C. ORLANDO, M.D.; PHILLIP MOYER, M.D.; THOMAS B. BARNETT, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Methysergide is an ergot alkaloid useful in the treatment of migraine headache. In 1964, Graham (1) described two patients on chronic methysergide therapy who developed retroperitoneal fibrosis. Since then, fibrosis associated with methysergide has also been reported to involve the pleura, lung, endocardium, heart valves, and great vessels (1-3). We describe a patient who developed constrictive pericarditis while on chronic methysergide therapy.
A 77-year-old woman was admitted to North Carolina Memorial Hospital with dyspnea and edema. Five years earlier she was evaluated at an affiliated hospital for a right pleural effusion and pleural fibrosis. At that time, skin testing with
ORLANDO RC, MOYER P, BARNETT TB. Methysergide Therapy and Constrictive Pericarditis. Ann Intern Med. ;88:213–214. doi: 10.7326/0003-4819-88-2-213
Download citation file:
Published: Ann Intern Med. 1978;88(2):213-214.
Cardiology, Pericardial Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use